Diagnostic Code 7719 · 38 CFR §4.117
Chronic myelogenous leukemia (CML) is a cancer of the bone marrow where a genetic mutation (Philadelphia chromosome) causes overproduction of myeloid white blood cells. CML progresses through three phases: chronic phase (manageable), accelerated phase (worsening), and blast crisis (acute leukemia). Modern treatment with tyrosine kinase inhibitors (such as imatinib) has transformed CML into a manageable chronic condition for many patients, but lifelong treatment is typically required. For veterans, CML may be linked to radiation exposure, benzene exposure, or other toxic exposures during service.
| Rating | Criteria |
|---|---|
| 100% | Active CML or during treatment. When the disease is in complete molecular remission on maintenance therapy, the VA reassesses based on treatment requirements and residual effects. |
Blood tests and bone marrow biopsy confirming the Philadelphia chromosome or BCR-ABL mutation are diagnostic. Hematology and oncology treatment records documenting the treatment regimen are needed. Service records showing radiation or chemical exposure help establish nexus. A nexus opinion from an oncologist or hematologist is recommended for non-presumptive claims.
The VA may reassess after a period of stable remission. However, the need for ongoing daily medication and monitoring typically supports a continued rating. Work with your VSO if a reduction is proposed.